Acute stroke treatment Tim Harrington. Important concepts All time loss/wastage results in further neuronal loss/poorer outcome The rate at which neuronal.

Slides:



Advertisements
Similar presentations
Imaging Overview DIAS-4. Randomised, double-blind, parallel-group, placebo- controlled phase III study to evaluate the efficacy and safety of desmoteplase.
Advertisements

Dr R. Anjan Bharathi. 3 rd leading cause of mortality & morbidity. Goal of imaging Early and accurate diagnosis Information about the intracranial vasculature.
Some Difficult Stroke Cases: What Would You Do?
Beyond the Basics of Stroke Evaluation
Pathophysiology of Stroke Sid M
Advances in Emergency Brain Imaging Andrew W. Asimos, MD Director of Emergency Stroke Care Carolinas Medical Center Charlotte, NC.
Thrombolysis for stroke in older people.
The NINDS rt-PA Stroke Trial Prior information(Pre-Clinical, Phase I Studies, etc) Thrombolytic canalization of occluded arteries may reduce the degree.
Neuroprotection Provided by Local Administration of Low- Dose Cold Albumin in Acute Ischemic Stroke Vance Fredrickson Wayne State University School of.
Role of CT in Acute Stroke Dr. PG Sridhar Sr. Consultant.
Advanced Treatment Options for Stroke Patients Vickie Gordon PhD, ACNP-BC, CNRN.
Quantitative MR Imaging of Acute Stroke
Anticoagulation in Acute Ischemic Stroke. TPA: Tissue Plasminogen Activator 1995: NINDS study of TPA administration Design: randomized, double blind placebo-controlled.
Brain Single-Photon Emission CT With HMPAO and Safety of Thrombolytic Therapy in Acute Ischemic Stroke Proceedings of the Meeting of the SPECT Safe Thrombolysis.
Ischemic Stroke Time is Brain: Or Is It?
Neuroimaging of Ischemic Stroke With CT and MRI
Andrew W. Asimos, MD How Can We Use Advanced Neuroimaging in the ED to Optimize Treatment Options for Acute Stroke Patients?
Diagnostic and Therapeutic Options for Emergency Stroke Care: Perspectives from the US, Italy, and Developing Countries Andrew W. Asimos, MD Director of.
IST-3 – an imaging substudy Dr Ingrid Kane Clinical research fellow.
Consultant Neurologist,
Interventional Stroke Treatment 2015
Dr Kneale Metcalf Stroke Physician (NNUHFT)
2015 Joint Congress on Medical Imaging and Radiation Sciences Imaging and Intervention in Acute Stroke: MR Imaging in Acute Stroke Viesha Ciura, MD, FRCPC.
The need for trials of i.v. thrombolysis in acute ischaemic stroke 10 th January 2008.
Interventions in Acute Ischemic Stroke: Strategies for the New Millennium For the next 25 minutes, we will spend sometime talking about Neuroimaging.
Stroke and the ED Kurian Thomas, MD Department of Neurology.
What’s on the horizon? Peter Sandercock ESC Lisbon 23rd May 2012.
Thrombolysis in acute ischaemic stroke – Updated Cochrane Thrombolysis metaanalysis JM Wardlaw, V Murray, PAG Sandercock University of Edinburgh and Karolinska.
Overview of new acute stroke trials Shawna Cutting, MD, MS Rush University Medical Center June 9, 2015.
Animal Models of Stroke Are they valuable for discovering neuroprotective agents? Wu Li-ping
Intra - Arterial Thrombolysis for acute stroke
Andrew W. Asimos, MD How Can We Use Advanced Neuroimaging in the ED to Optimize Treatment Options for Acute Stroke Patients?
Treatment of Ischaemic Stroke The American Heart Association American Stroke Association Guidelines Stroke. 2007;38:
Mr X, 79 years old Admitted on 5/5/00 to WGH stroke unit Dense (0/5) right arm and leg paresis Aphasic CT scan excluded a bleed Given trial treatment (IST-3)
Thrombolysis for patients > 80 – a different view Peter Sandercock On behalf of the IST3 collaborative Group UKSF Glasgow 1 st December 2009.
Recognition and Treatment of Large MCA Strokes Matthew S. Smith, MD, MS Director of Neurocritical Care Assistant Professor of Neurology Assistant Professor.
Thrombolysis: The Evidence Barry Moynihan Stroke Physician, St. George’s Hospital SITS/BASP Thrombolysis Nursing Training Day March 26 th 2012.
IST-3, SITS MOST ECASS-3 & DEFUSE Professor Peter Sandercock University of Edinburgh, UK ESC May 30 th 2007 Glasgow Competing interests:
Morphological and clinical results of invasive intra-arterial recanalization in the event of an acute stroke I Gubucz, Z Berentei, M Marosfői, C Óváry,
before thrombolysis in acute stroke
A multimodal step-up approach as rescue therapy of ischemic stroke L. Verganti, S. Vallone, C. Moratti, M. Malagoli, P. Carpeggiani Department of Neuroscience,
Kim, Sun-Yong, M.D. Department of Radiology Ajou University Hospital, Suwon, Korea AGGRESIVE MECHANICAL CLOT DISRUPTION FOR ACUTE ISCHEMIC STROKE WITH.
Certainty of Stroke Diagnosis: Incremental Benefit with CT Perfusion over NC-CT & CTA Richard I. Aviv, Julia Hopyan, Anthony Ciarallo, et al (including.
Time Is Brain: Advanced Stroke Treatment Grahame C Gould, MD Jefferson Neurosurgical Associates at Main Line Health, Bryn Mawr Hospital Division of Neurovascular.
New ways of imaging Stroke/TIA Dr Suzanne O’Leary Neuroradiology SpR Frenchay Hospital.
ACUTE TREATMENT OF STROKE: RECENT ADVANCES AND PERFORMANCE AT CAMPBELLTOWN ALEX BUTTFIELD ED STAFF SPECIALIST.
ACUTE STROKE TREATMENT: An introduction Dec.2014
High-risk ST elevation MI patients (>4 mm elevation), Sx < 12 hrs 5 PCI centers (n=443) and 22 referring hospitals (n=1,129), transfer in < 3 hrs High-risk.
Abstract No: eEdE-103 Submission Number: Disclosure There is no disclosure.
Update on Stroke GP Update Course RSCH October 2010 Dr Adrian Blight.
Dr Marc Randall Consultant Neurologist and Stroke Physician Honorary Senior Lecturer University Sheffield.
Treating Acute Ischemic Stroke, Can We Open Up the Time Window?
Neuroradiology of Stroke and Headaches
Acute Stroke Management
Thrombectomy in Acute Stroke
Sameer A. Ansari, MD, PhD Associate Professor
Acute Carotid Occlusions
Acute Stroke Therapy with IV Thrombolysis Lawrence R. Wechsler, M.D.
Evidence-Base Medicine
When Not to Intervene in Acute Stroke or
Stroke imaging M3 radiology August 2014.
Icahn School of Medicine Mount Sinai Hospital
Setareh Omran, MD Vascular Neurology Fellow
Update from education committee
Acute Ischemic Stroke First Eight Hours Dr. Mohammed Ateequr Rahman
Modified Rankin score 0-2
Extended Window Thrombectomy
A 92-year-old man presented with left hemiparesis, dysarthria, hemianopia and inattention National Institutes of Health Stroke Scale (NIHSS) 19. A 92-year-old.
A 76-year-old man presenting with acute right-sided symptoms.
CT Perfusion Basics.
Presentation transcript:

Acute stroke treatment Tim Harrington

Important concepts All time loss/wastage results in further neuronal loss/poorer outcome The rate at which neuronal loss occurs is highly variable variations in COW and pial collaterals Penumbra- injured but resurrectable brain Patient selection is critical and is still controversial CTP not reliable, MRP not readily available IV and IA have differing strengths and weaknesses

Variability and reversibility of focal cerebral ischaemia in unanesthetized monkeys Cromwell RM et al Stroke lab, Uni of Massachusetts Neurology October (10): ‘neurologic improvement was common after the release of occlusion. …frequent with 30-min and 4- hour occlusions …was observed even after 16 hours’

CONCEPTS INFARCT CORE ISCHAEMIC PENUMBRA

concepts Core of irreversible injury Penumbra sustained by peripheral collaterals: potentially salvageable with prompt institution of appropriate therapy

Aims Recannalisation Minimal delay Minimal Cx- nb sICH Optimise physiological parameters to minimise cerebral compromise

What do we know? Most of morbidity and mortality comes from large vessel occlusions - 46% of stroke involve large vessel occlusions and these have a poor prognosis (eg Basilar or ICA occlusion have 4.5 fold ↑ risk of death and 3 fold ↓risk of good outcome)- Smith WS et al Stroke 2009 Recanalisation associated with good outcome- 58 vs 25% Rha Stroke 2007 Higher rates of recanalisation with arterial embolectomy than IV tPA especially in the vessels that IV tPA is ineffective

Neuronal loss 32,000 neurones/min Average Individual rates are highly variable and depend mainly on quality/quantity of pial and other collateral other drivers of perfusion such as BP

Time A protocol that allows up to 4.5hrs does not mean that much time should be used up Procedural time is often one of the least important delays in achieving recannalisation

Time A successful acute stroke program will address delays throughout the treatment pathway Public information re nature of stroke and urgency Ambulance diversion to stroke centres Rapid triage and informing of relevant teams Imaging urgency Parallel arrangement of consent, ICU, aneasthetics, bloods whilst waiting for other steps

IV Thrombolysis Almost 20yrs old and still only <20% being treated in western countries- bolus + 1hr infusion Only requires NCCT for triage many contraindications- mainly re bleeding risk not effective in large vessels newer agents more fibrin specific eg Tenectoplase Advanced imaging hoping to improve pt selection

IV Thrombolysis 38% good outcome in NINDS in strokes selected for small size by clinical stroke score recannalisation <10% in ICA, <25% in M1 Approx 9% sICH Tenectoplase- ↑recannalisation, ↑neurological improvement Parsons et al rtPA approved to 4.5hrs

Patient selection Time is a poor surrogate for knowing an individual’s pathophysiology Assessing ‘penumbra’ CTA and CTP whilst not having full validation proving to be useful tools and readily available- adds about 15min to NCCT

NECT Haemorrhage Cytotoxic oedema Dense MCA sign

Lentiform nucleus

Insular stripe

Hyperdense MCA

MRI DWI measures “water motion” Ischaemia: normal cellular ion pumps (eg Na-K) fail Shift of water from extracellular to intracellular space Cytotoxic oedema Restricted diffusion

CT perfusion Can be used to measure perfusion parameters CBV CBF MTT

cerebral blood volume Volume of blood per unit of brain tissue 4-5mL/100g

cerebral blood flow Blood flow per unit of brain tissue per minute 50-60mL/100g/min

MEAN TRANSIT TIME Time difference between arterial inflow and venous outflow

CEREBRAL ISCHAEMIA Decreased CBF Cerebral autoregulation Capillary dilatation

CAPILLARY DILATATION Increased CBV Increased MTT

CRITICAL CBF LOSS Normally 20% Failure of autoregulation Reduction in CBV Reduction in CBF

Imaging the core MRI DWI Visible hypo- attenuation of NECT rarely reverses CBV abnormality on Perfusion

IMAGING THE PENUMBRA Increased MTT Normal CBV

CTA Site of occlusion length of occlusion Tandem lesions- ICA source of embolus Access issues

Level & Access

Imaging Core CBV or DWI Poor chance of good outcome if >25ml Almost no chance of good outcome if >70ml Severe perfusion changes predicts ICH TTP >14sec

Poor collateral/CTP 2hrs

Poor collaterals/CTP

Good collaterals/CTP at 8hrs

Good collaterals/CTP

IA therapy/embolecto my Stentriever- Solitaire, Trevo, others Direct aspiration- Penumbra Combination of above

4545

4646

What do we know? iv tPA fails to recannalise in most large vessel occlusions-25% success in M1,10% for ICA Most patients do not receive iv tPA- at best 20% - time and other exclusions Imaging can select gps with salvageable brain beyond 3-4.5hr time window Abou-Chebl A Stroke 2010

Efficacy? Recannalisation rates of 80-90% Average times to recann. of 40min Frequent single pass recann-average no of passes 1.8

Outcomes Miteff F- mRS≤2 in 56% ant circ’n 16pts Galimanis A et al-623 pts prospective-48.9% Soize S et al-36pts prospective- 63.9% STAR- prospective registry multinational -58%

83yo female SUDDEN COLLAPSE DYSPHASIA

Blood volume

Mean transit time

PROCEDURE TIME: 15 MIN SINGLE PASS

IV vs IA IMS 111 failed but wrong devices used with unacceptable delays Randomised trials in US, Europe and Aus

Evolving Protocol Clinical then CT work-up NCCT,CTA,CTP IV rTPA in those suitable Endovascular immediately in those with large vessel occlusion

Treatment selection IV tPA has limit on size of vessel/thrombus it can dissolve longer than 8mm embolus has 0 recann should have occurred within 1hr of injection Quick and no skill in delivery, can be used after limited imaging( NCCT as per NINDS) ‘drip and ship’ model

Treatment selection Arterial treatment restricted to large vessels ICA, M1/2,Basilar these are most morbid strokes Technical issues/skill important access difficult in elderly- ?restrict to <80yrs Not interfered with by prior tPA and not limited by tPA limitations

Treatment synergy IV and IA are not really the competitors they are made out to be Interested in different vessels Extend IA- IV vs IV plus IA, similar UK/European studies IMS 111- poor devices and prolonged delays in IA Rx

Treatment selection IV thrombolysis- rTPA, tenectoplase IA stentriever aspiration IA thrombolysis

Thank You